Xin Wang

List of Publications by Year
in descending order

63	1,481	331259 21	377514 34
papers	citations	h-index	g-index

63	63	63	1969
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Current trends in drug metabolism and pharmacokinetics. Acta Pharmaceutica Sinica B, 2019, 9, 1113-1144.	5.7	147
2	Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer. Nature Communications, 2016, 7, 13122.	5.8	76
3	Major tanshinones of Danshen (Salvia miltiorrhiza) exhibit different modes of inhibition on human CYP1A2, CYP2C9, CYP2E1 and CYP3A4 activities in vitro. Phytomedicine, 2010, 17, 868-875.	2.3	71
4	Inhibitory effects of celastrol on rat liver cytochrome P450 1A2, 2C11, 2D6, 2E1 and 3A2 activity. FÃ¬toterapÃ¬Ã¢, 2014, 92, 1-8.	1.1	62
5	5-Fluorouracil Derivatives from the SpongePhakellia fusca. Journal of Natural Products, 2003, 66, 285-288.	1.5	60
6	Reprogramming immunosuppressive myeloid cells facilitates immunotherapy for colorectal cancer. EMBO Molecular Medicine, 2021, 13, e12798.	3.3	59
7	New insights of CYP1A in endogenous metabolism: a focus on single nucleotide polymorphisms and diseases. Acta Pharmaceutica Sinica B, 2020, 10, 91-104.	5.7	58
8	Systemic regulation of L-carnitine in nutritional metabolism in zebrafish, Danio rerio. Scientific Reports, 2017, 7, 40815.	1.6	53
9	Characterization of novel cytochrome P450 2E1 knockout rat model generated by CRISPR/Cas9. Biochemical Pharmacology, 2016, 105, 80-90.	2.0	43
10	CRISPR knockout rat cytochrome P450 3A1/2 model for advancing drug metabolism and pharmacokinetics research. Scientific Reports, 2017, 7, 42922.	1.6	41
11	Role of vitamin D receptor in the regulation of CYP3A gene expression. Acta Pharmaceutica Sinica B, 2019, 9, 1087-1098.	5.7	39
12	Discovery and Characterization of 1H-1,2,3-Triazole Derivatives as Novel Prostanoid EP4 Receptor Antagonists for Cancer Immunotherapy. Journal of Medicinal Chemistry, 2020, 63, 569-590.	2.9	32
13	Effects of major tanshinones isolated from Danshen (Salvia miltiorrhiza) on rat CYP1A2 expression and metabolism of model CYP1A2 probe substrates. Phytomedicine, 2009, 16, 712-725.	2.3	31
14	Evaluation of the inhibition potential of plumbagin against cytochrome P450 using LC-MS/MS and cocktail approach. Scientific Reports, 2016, 6, 28482.	1.6	31
15	Design and Optimization of Novel Hydroxamate-Based Histone Deacetylase Inhibitors of Bis-Substituted Aromatic Amides Bearing Potent Activities against Tumor Growth and Metastasis. Journal of Medicinal Chemistry, 2014, 57, 9357-9369.	2.9	30
16	Assessment of the inhibition risk of shikonin on cytochrome P450 via cocktail inhibition assay. Toxicology Letters, 2017, 281, 74-83.	0.4	29
17	Modification and Biological Evaluation of a Series of 1,5-Diaryl-1,2,4-triazole Compounds as Novel Agents against Pancreatic Cancer Metastasis through Targeting Myoferlin. Journal of Medicinal Chemistry, 2019, 62, 4949-4966.	2.9	27
18	Diet-induced obese alters the expression and function of hepatic drug-metabolizing enzymes and transporters in rats. Biochemical Pharmacology, 2019, 164, 368-376.	2.0	26

#	Article	IF	Citations
19	Effects of Salvia miltiorrhiza Extract on the Liver CYP3A Activity in Humans and Rats. Phytotherapy Research, 2011, 25, 1653-1659.	2.8	23
20	Characterization of organic anion transporting polypeptide 1b2 knockout rats generated by CRISPR/Cas9: a novel model for drug transport and hyperbilirubinemia disease. Acta Pharmaceutica Sinica B, 2020, 10, 850-860.	5.7	23
21	A pharmacodynamicâ€“pharmacokinetic (PDâ€“PK) study on the effects of Danshen (Salvia miltiorrhiza) on midazolam, a model CYP3A probe substrate, in the rat. Phytomedicine, 2010, 17, 876-883.	2.3	22
22	Inhibitory effect of tanshinones on rat CYP3A2 and CYP2C11 activity and its structure-activity relationship. FÃ¬toterapÃ¬Ã¢, 2011, 82, 539-545.	1.1	22
23	Development and Characterization of MDR1 (Mdr1a/b) CRISPR/Cas9 Knockout Rat Model. Drug Metabolism and Disposition, 2019, 47, 71-79.	1.7	22
24	Investigation of cytochrome P450 inhibitory properties of maslinic acid, a bioactive compound from Olea europaea L., and its structureâ€“activity relationship. Phytomedicine, 2015, 22, 56-65.	2.3	21
25	A Novel Model of Pâ€Glycoprotein Inhibitor Screening Using Human Small Intestinal Organoids. Basic and Clinical Pharmacology and Toxicology, 2017, 120, 250-255.	1.2	21
26	Quantification of nucleotides and their sugar conjugates in biological samples: Purposes, instruments and applications. Journal of Pharmaceutical and Biomedical Analysis, 2018, 158, 280-287.	1.4	20
27	Effects of the aqueous extract from Salvia miltiorrhiza Bunge on caffeine pharmacokinetics and liver microsomal CYP1A2 activity in humans and rats. Journal of Pharmacy and Pharmacology, 2010, 62, 1077-1083.	1.2	19
28	Investigation of cytochrome P450 1A2 and 3A inhibitory properties of Danshen tincture. Phytomedicine, 2012, 19, 348-354.	2.3	18
29	CRISPR-Cas9: A method for establishing rat models of drug metabolism and pharmacokinetics. Acta Pharmaceutica Sinica B, 2021, 11, 2973-2982.	5.7	18
30	Inhibited Carnitine Synthesis Causes Systemic Alteration of Nutrient Metabolism in Zebrafish. Frontiers in Physiology, 2018, 9, 509.	1.3	17
31	Design and optimization of the cocktail assay for rapid assessment of the activity of UGT enzymes in human and rat liver microsomes. Toxicology Letters, 2018, 295, 379-389.	0.4	17
32	A Novel TGR5 Activator WB403 Promotes GLP-1 Secretion and Preserves Pancreatic Î²-Cells in Type 2 Diabetic Mice. PLoS ONE, 2015, 10, e0134051.	1.1	16
33	A novel biosensor based on intestinal 3D organoids for detecting the function of BCRP. Drug Delivery, 2017, 24, 1453-1459.	2.5	16
34	Pharmacokinetics of metronidazole in pregnant patients with bacterial vaginosis. Journal of Maternal-Fetal and Neonatal Medicine, 2011, 24, 444-448.	0.7	15
35	Comprehensive assessment of Cucurbitacin E related hepatotoxicity and drug-drug interactions involving CYP3A and P-glycoprotein. Phytomedicine, 2017, 26, 1-10.	2.3	15
36	Cytochrome P450 3A selectively affects the pharmacokinetic interaction between erlotinib and docetaxel in rats. Biochemical Pharmacology, 2017, 143, 129-139.	2.0	15

#	Article	IF	Citations
37	Plant natural product plumbagin presents potent inhibitory effect on human cytochrome P450 2J2 enzyme. Phytomedicine, 2018, 39, 137-145.	2.3	15
38	Measurement of Rhodamine 123 in Threeâ€Dimensional Organoids: A Novel Model for Pâ€Glycoprotein Inhibitor Screening. Basic and Clinical Pharmacology and Toxicology, 2016, 119, 349-352.	1.2	14
39	The burgeoning role of cytochrome P450-mediated vitamin D metabolites against colorectal cancer. Pharmacological Research, 2018, 133, 9-20.	3.1	14
40	3D organoids derived from the small intestine: An emerging tool for drug transport research. Acta Pharmaceutica Sinica B, 2021, 11, 1697-1707.	5.7	14
41	Effects of Cucurbitacin E, a Tetracyclic Triterpene Compound from Cucurbitaceae, on the Pharmacokinetics and Pharmacodynamics of Warfarin in Rats. Basic and Clinical Pharmacology and Toxicology, 2015, 116, 385-389.	1.2	13
42	Preclinical toxicology and toxicokinetic evaluation of ailanthone, a natural product against castration-resistant prostate cancer, in mice. FÃ¬toterapÃ¬Ã¢, 2019, 136, 104161.	1.1	13
43	Design, synthesis and evaluation of hybrid of tetrahydrocarbazole with 2,4-diaminopyrimidine scaffold as antibacterial agents. European Journal of Medicinal Chemistry, 2019, 162, 203-211.	2.6	13
44	New insights into the androgen biotransformation in prostate cancer: A regulatory network among androgen, androgen receptors and UGTs. Pharmacological Research, 2016, 106, 114-122.	3.1	12
45	Generation and Characterization of Cytochrome P450 2J3/10 CRISPR/Cas9 Knockout Rat Model. Drug Metabolism and Disposition, 2020, 48, 1129-1136.	1.7	12
46	Investigation of the content differences of arachidonic acid metabolites in a mouse model of breast cancer by using LCâ€“MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2021, 194, 113763.	1.4	12
47	Development of a validated LCâ€“MS/MS method for the determination of ailanthone in rat plasma with application to pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2015, 102, 514-518.	1.4	9
48	Evaluation of the inhibition risk of shikonin on human and rat UDP-glucuronosyltransferases (UGT) through the cocktail approach. Toxicology Letters, 2019, 312, 214-221.	0.4	9
49	Organic anion transport polypeptide 1b2 selectively affects the pharmacokinetic interaction between paclitaxel and sorafenib in rats. Biochemical Pharmacology, 2019, 169, 113612.	2.0	8
50	CYP3A deficiency alters bile acid homeostasis and leads to changes in hepatic susceptibility in rats. Toxicology and Applied Pharmacology, 2021, 429, 115703.	1.3	8
51	An orally available small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth in vitro and in vivo. Cancer Letters, 2022, 529, 100-111.	3.2	8
52	LG308, a Novel Synthetic Compound with Antimicrotubule Activity in Prostate Cancer Cells, Exerts Effective Antitumor Activity. Journal of Pharmacology and Experimental Therapeutics, 2015, 355, 473-483.	1.3	7
53	Characterization of a Novel CYP1A2 Knockout Rat Model Constructed by CRISPR/Cas9. Drug Metabolism and Disposition, 2021, 49, 638-647.	1.7	7
54	Evaluation of enzyme inhibition kinetics in drugâ€“drug interactions. Chemico-Biological Interactions, 2014, 222, 133-134.	1.7	6

#	Article	IF	Citations
55	Construction and Characterization of CRISPR/Cas9 Knockout Rat Model of Carboxylesterase 2a Gene. Molecular Pharmacology, 2021, 100, 480-490.	1.0	6
56	In vitro and in vivo evaluation of cucurbitacin E on rat hepatic CYP2C11 expression and activity using LC-MS/MS. Science China Life Sciences, 2017, 60, 215-224.	2.3	5
57	Characterization of in vitro Mrp2 transporter model based on intestinal organoids. Regulatory Toxicology and Pharmacology, 2019, 108, 104449.	1.3	5
58	Establishment of LC-MS/MS method for determination of aloperine in rat plasma and its application in preclinical pharmacokinetics. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1173, 122671.	1.2	5
59	Lactobacillus rhamnosus induces CYP3A and changes the pharmacokinetics of verapamil in rats. Toxicology Letters, 2021, 352, 46-53.	0.4	5
60	A note on CYP2J2-mediated terfenadine hydroxylation in human liver microsomes. Food and Chemical Toxicology, 2014, 71, 284-285.	1.8	3
61	Risk assessment of the inhibition of hydroxygenkwanin on human and rat cytochrome P450 by cocktail method. Toxicology in Vitro, 2022, 79, 105281.	1.1	2
62	Assessment of the inhibition risk of paris saponins, bioactive compounds from Paris polyphylla, on CYP and UGT enzymes via cocktail inhibition assays. Regulatory Toxicology and Pharmacology, 2020, 113, 104637.	1.3	1
63	P-glycoprotein mediates the pharmacokinetic interaction of olanzapine with fluoxetine in rats. Toxicology and Applied Pharmacology, 2021, 431, 115735.	1.3	0